Fulgent Genetics's earnings per share without non-recurring items for the
three
months ended in Dec. 2023 was $0.28.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.06.
During the past 12 months, Fulgent Genetics's average earnings per share (NRI) Growth Rate was -151.90% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Fulgent Genetics's EPS without NRI or its related term are showing as below:
During the past 10 years, Fulgent Genetics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 72.90% per year. The lowest was -21.50% per year. And the median was 7.40% per year.
FLGT's 3-Year EPS without NRI Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.3 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
Fulgent Genetics's EPS (Diluted) for the
three
months ended in Dec. 2023 was $-4.30.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.64.
Fulgent Genetics's EPS (Basic) for the
three
months ended in Dec. 2023 was $-4.30.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.64.
Fulgent Genetics EPS without NRI Historical Data
The historical data trend for Fulgent Genetics's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Fulgent Genetics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulgent Genetics PE Ratio without NRI Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Fulgent Genetics's PE Ratio without NRI falls into.
Fulgent Genetics EPS without NRI Calculation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.06
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fulgent Genetics (NAS:FLGT) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Fulgent Genetics EPS without NRI Related Terms
Thank you for viewing the detailed overview of Fulgent Genetics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.
Fulgent Genetics (Fulgent Genetics) Business Description
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FLGT has been successfully added to your 